Two Phase 3 Studies on Ophthalmologic Effects of Roxadustat Versus Darbepoetin

INTRODUCTION: Roxadustat is an orally administered hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that represents a novel therapeutic option for patients with anemia of chronic kidney disease (CKD). METHODS: Conducted in Japan, CL-0307 (NCT02952092) and CL-310 (NCT02988973) were phase 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Sepah, Yasir J., Nguyen, Quan Dong, Yamaguchi, Yusuke, Otsuka, Tetsuro, Majikawa, Yoshikatsu, Reusch, Michael, Akizawa, Tadao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039484/
https://www.ncbi.nlm.nih.gov/pubmed/35497806
http://dx.doi.org/10.1016/j.ekir.2022.01.1045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039484/
https://www.ncbi.nlm.nih.gov/pubmed/35497806
http://dx.doi.org/10.1016/j.ekir.2022.01.1045

Ejemplares similares